Richard Eric Davis
Impact in
- Genetics top 0.1%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment
Papers in
-
- Lymphoma Diagnosis and Treatment 61
- Hematology 49
- Multiple Myeloma Research and Treatments 24
- Co-authors
- Louis M. Staudt (17 shared papers)Ulrich K. Siebenlist (1 shared paper)Keith D. Brown (1 shared paper)Lloyd T. Lam (7 shared papers)John I. Powell (3 shared papers)Xin Yu (3 shared papers)Wencai Ma (25 shared papers)Georg Lenz (4 shared papers)
- Journals
- Blood (61 papers)British Journal of Haematology (7 papers)Leukemia (6 papers)Clinical Cancer Research (6 papers)Cancer Cell (4 papers)
- Partner nations
- United StatesChinaGermany
In The Last Decade
Richard Eric Davis
196 papers receiving 18.0k citations
Richard Eric Davis's Hit Papers
Peers
Comparison fields: 5 of 140
- Genetics 3.9k
- Pathology and Forensic Medicine 5.5k
- Oncology 6.6k
- Immunology 5.2k
- Hematology 2.4k
Countries citing papers authored by Richard Eric Davis
This map shows the geographic impact of Richard Eric Davis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Richard Eric Davis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Richard Eric Davis more than expected).
Fields of papers citing papers by Richard Eric Davis
This network shows the impact of papers produced by Richard Eric Davis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Richard Eric Davis. The network helps show where Richard Eric Davis may publish in the future.
Co-authors
The 25 scholars most cited alongside Richard Eric Davis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 202 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Hit paper breakdown → | 2010 | 1365 |
| 2 | Constitutive Nuclear Factor κB Activity Is Required for Survival of Activated B Cell–like Diffuse Large B Cell Lymphoma Cells Hit paper breakdown → | 2001 | 907 |
| 3 | Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia Hit paper breakdown → | 2001 | 883 |
| 4 | Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma Hit paper breakdown → | 2007 | 821 |
| 5 | Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade Hit paper breakdown → | 2016 | 817 |
| 6 | Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways Hit paper breakdown → | 2008 | 802 |
| 7 | Oncogenic CARD11 Mutations in Human Diffuse Large B Cell Lymphoma Hit paper breakdown → | 2008 | 726 |
| 8 | 2006 | 509 | |
| 9 | Increased Tumor Glycolysis Characterizes Immune Resistance to Adoptive T Cell Therapy Hit paper breakdown → | 2018 | 497 |
| 10 | Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas Hit paper breakdown → | 2020 | 480 |
| 11 | 1998 | 464 | |
| 12 | Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial Hit paper breakdown → | 2013 | 462 |
| 13 | 2013 | 397 | |
| 14 | 2007 | 315 | |
| 15 | 2014 | 313 | |
| 16 | Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. | 2005 | 282 |
| 17 | 2019 | 282 | |
| 18 | 1995 | 277 | |
| 19 | 2012 | 265 | |
| 20 | 2014 | 242 |
About Richard Eric Davis
Richard Eric Davis is a scholar working on Pathology and Forensic Medicine, Hematology, Oncology, Immunology and Genetics, having authored 202 papers that have together received 18.3k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (61 papers), Chronic Lymphocytic Leukemia Research (24 papers), Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (20 papers), Protein Degradation and Inhibitors (18 papers), Immunotherapy and Immune Responses (18 papers), Immune Cell Function and Interaction (16 papers) and Ubiquitin and proteasome pathways (15 papers). The work is most often cited by research in Genetics (3.9k citations), Pathology and Forensic Medicine (5.5k citations), Oncology (6.6k citations), Immunology (5.2k citations) and Hematology (2.4k citations). Richard Eric Davis has collaborated with scholars based in United States, China and Germany. Frequent co-authors include Louis M. Staudt, Ulrich K. Siebenlist, Keith D. Brown, Lloyd T. Lam, John I. Powell, Xin Yu, Wencai Ma, Georg Lenz, Zhiqiang Wang and Lenny Dang. Their work appears in journals such as Blood, British Journal of Haematology, Leukemia, Clinical Cancer Research and Cancer Cell.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.